TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

Interaction of myeloma cells with the bone marrow microenvironment is mediated in large part through different cytokines, especially VEGF and IL6. These cytokines, especially IL6, leads to up-regulation of the JAK/STAT pathway in myeloma cell, contributing to increased proliferation, decreased apopt...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ramakrishnan, Vijay, Kimlinger, Teresa, Haug, Jessica, Timm, Michael, Wellik, Linda, Halling, Timothy, Pardanani, Animesh, Tefferi, Ayalew, Rajkumar, S. Vincent, Kumar, Shaji
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940994/
https://ncbi.nlm.nih.gov/pubmed/20652971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21785
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak